Sanofi $SNY Shares Bought by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC grew its holdings in shares of Sanofi (NASDAQ:SNY) by 3.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 349,701 shares of the company’s stock after purchasing an additional 10,264 shares during the period. Janney Montgomery Scott LLC’s holdings in Sanofi were worth $16,894,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Accent Capital Management LLC bought a new position in shares of Sanofi during the first quarter worth about $29,000. Eastern Bank grew its position in shares of Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after acquiring an additional 300 shares during the last quarter. Banque Transatlantique SA bought a new position in shares of Sanofi during the first quarter worth about $33,000. Golden State Wealth Management LLC grew its position in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock worth $35,000 after acquiring an additional 545 shares during the last quarter. Finally, Brentview Investment Management LLC bought a new position in shares of Sanofi during the first quarter worth about $42,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Trading Up 0.8%

Shares of SNY opened at $50.14 on Friday. The business’s 50-day moving average price is $48.18 and its 200 day moving average price is $50.15. The stock has a market capitalization of $123.12 billion, a P/E ratio of 12.05, a P/E/G ratio of 1.18 and a beta of 0.51. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same quarter last year, the company posted $1.73 EPS. The firm’s revenue was down 7.0% compared to the same quarter last year. Analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on SNY shares. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and a consensus target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.